MDT-AP-2579
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 59.04
- os_event
- false
- age_years
- 9
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.931662332
- umap2_2d
- 5.486824751
- umap1_3d
- 2.359809291
- umap2_3d
- -0.109829219
- umap3_3d
- -1.49599302
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.360
- MYOGENESIS+0.330
- PANCREAS_BETA_CELLS+0.330
- INFLAMMATORY_RESPONSE+0.310
- INTERFERON_GAMMA_RESPONSE+0.300
- COMPLEMENT+0.280
- INTERFERON_ALPHA_RESPONSE+0.280
- ALLOGRAFT_REJECTION+0.270
- COAGULATION+0.270
- ESTROGEN_RESPONSE_LATE+0.250
Top 10 suppressed
- MYC_TARGETS_V1-0.530
- G2M_CHECKPOINT-0.510
- E2F_TARGETS-0.490
- MITOTIC_SPINDLE-0.490
- MYC_TARGETS_V2-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.410
- DNA_REPAIR-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
- MTORC1_SIGNALING-0.290
- PI3K_AKT_MTOR_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598269 | fetal | fetal | 0.908 |
| 2 | SRR1364739 | GTEX | — | 0.904 |
| 3 | ERR2598336 | fetal | fetal | 0.903 |
| 4 | ERR2598288 | fetal | fetal | 0.900 |
| 5 | MDT-AP-2047 | Med | Medulloblastoma | 0.893 |
| 6 | MDT-AP-2130 | Med | Medulloblastoma | 0.892 |
| 7 | MDT-AP-2283 | Med | Medulloblastoma | 0.888 |
| 8 | ERR2598329 | fetal | fetal | 0.886 |
| 9 | SRR1458180 | GTEX | — | 0.885 |
| 10 | ERR2598335 | fetal | fetal | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |